# OnCo record paper-tcga-molecular-taxonomy-primary-prostate-cell-2015 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-tcga-molecular-taxonomy-primary-prostate-cell-2015/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-tcga-molecular-taxonomy-primary-prostate-cell-2015" ;
  schema:name "TCGA: the molecular taxonomy of primary prostate cancer"@en ;
  schema:alternateName "TCGA prostate 2015"@en, "molecular taxonomy primary prostate cancer"@en, "seven subtypes prostate"@en ;
  schema:description "The Cancer Genome Atlas classified 333 prostate cancers taken out at surgery and found that three quarters fall into one of seven groups defined by a fusion or a mutation. A quarter had a change that a drug could in principle be aimed at, and one in five had a broken DNA repair gene."@en ;
  schema:url <https://onco.cc/key-papers/paper-tcga-molecular-taxonomy-primary-prostate-cell-2015/> ;
  schema:dateModified "2026-09-25"^^xsd:date ;
  schema:citation <https://doi.org/10.1016/j.cell.2015.10.025>, <https://pubmed.ncbi.nlm.nih.gov/26544944/>, <https://portal.gdc.cancer.gov/projects/TCGA-PRAD>, <https://www.cbioportal.org/study/summary?id=prad_tcga_pub>, <https://www.cbioportal.org/study/summary?id=prad_tcga_pan_can_atlas_2018> ;
  onco:tag "prostate-evidence" ;
  schema:sameAs <https://doi.org/10.1016/j.cell.2015.10.025> ;
  schema:datePublished "2015"^^xsd:gYear ;
  schema:author "Cancer Genome Atlas Research Network." ;
  onco:related <https://onco.cc/key-papers/paper-robinson-integrative-clinical-genomics-advanced-prostate-cell-2015/>, <https://onco.cc/key-papers/paper-taylor-integrative-genomic-profiling-cancer-cell-2010/>, <https://onco.cc/key-papers/paper-capitello-281-ann-oncol-2026/>, <https://onco.cc/roadmaps/prostate-roadmap/> ;
  onco:cancers <https://onco.cc/cancers/prostate/>, <https://onco.cc/cancers/prostate-high-risk/> ;
  onco:sections <https://onco.cc/fronts/diagnostics/>, <https://onco.cc/fronts/targeted-therapy/> ;
  onco:technologies <https://onco.cc/technologies/wes-wgs/>, <https://onco.cc/technologies/rna-seq/> ;
  onco:targets <https://onco.cc/targets/spop/>, <https://onco.cc/targets/foxa1/>, <https://onco.cc/targets/erg/>, <https://onco.cc/targets/tmprss2/>, <https://onco.cc/targets/pten/>, <https://onco.cc/targets/pik3ca/>, <https://onco.cc/targets/androgen-receptor/>, <https://onco.cc/targets/brca/>, <https://onco.cc/targets/etv1/>, <https://onco.cc/targets/idh/>, <https://onco.cc/targets/tp53/> ;
  onco:pathways <https://onco.cc/pathways/prostate-cancer-signalling/>, <https://onco.cc/pathways/ar-signaling/>, <https://onco.cc/pathways/pi3k-akt-mtor/>, <https://onco.cc/pathways/ubiquitin-proteasome-system/>, <https://onco.cc/pathways/epigenetic-reprogramming/> ;
  onco:terms <https://onco.cc/terms/hrd/>, <https://onco.cc/terms/ngs/>, <https://onco.cc/terms/gene-fusion/>, <https://onco.cc/terms/driver-mutation/>, <https://onco.cc/terms/gleason-grade-group/>, <https://onco.cc/terms/somatic-mutations-wxs-wgs/> ;
  onco:bottlenecks <https://onco.cc/bottlenecks/b-biomarker-validation/>, <https://onco.cc/bottlenecks/b-tumor-heterogeneity/>, <https://onco.cc/bottlenecks/b-data-silos/> ;
  onco:journals <https://onco.cc/journals/cell/> .